Drug facts
BrandLenvima (Lenvatinib)
No generic lenvatinib is approved; the latest Lenvima patent or exclusivity in the Orange Book runs to 11/15/2038.
Lenvima was first approved by the FDA on 02/13/2015 under NDA 206947; the application holder is Eisai Inc.
Holder Eisai IncApplication NDA 206947Approved 02/13/2015
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
4,398days until the latest patent expires
ExclusivityPatent onlyOpen to generics
Today
Approved02/13/2015
Exclusivity ends10/03/2027
Last patent11/15/2038
2016202020242028203220362040
- Latest patent
- 11/15/2038Lenvima Orange Book
- Exclusivity
- 10/03/2027Lenvima Orange Book
02Competition
- Generics
- No generic approved Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Lenvima profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
04Product
- Application holder
- Eisai Inc Orange Book
- Application
- NDA 206947 Orange Book
- First approved
- 02/13/2015 Orange Book
- Dosage forms
- capsule
- Routes
- oral
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.